Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report published on Sunday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Shares of NASDAQ EGRX opened at $0.65 on Friday. The stock has a fifty day moving average of $0.73 and a 200-day moving average of $3.15. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $6.81.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC purchased a new stake in Eagle Pharmaceuticals in the second quarter valued at approximately $971,000. Jacobs Levy Equity Management Inc. bought a new stake in Eagle Pharmaceuticals in the third quarter worth $453,000. Jane Street Group LLC bought a new stake in shares of Eagle Pharmaceuticals in the 3rd quarter valued at about $96,000. Cubist Systematic Strategies LLC bought a new stake in Eagle Pharmaceuticals in the second quarter valued at approximately $145,000. Finally, AIGH Capital Management LLC increased its stake in shares of Eagle Pharmaceuticals by 2.1% in the second quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock worth $6,784,000 after buying an additional 25,000 shares during the period. 85.36% of the stock is currently owned by hedge funds and other institutional investors.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.